Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Detalles Bibliográficos
Autores principales: Tagawa, Scott T., Ramaswamy, Krishnan, Huang, Ahong, Mardekian, Jack, Schultz, Neil M., Wang, Li, Sandin, Rickard, Lechpammer, Stanislav, George, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705240/
https://www.ncbi.nlm.nih.gov/pubmed/35840724
http://dx.doi.org/10.1038/s41391-022-00578-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705240/
https://www.ncbi.nlm.nih.gov/pubmed/35840724
http://dx.doi.org/10.1038/s41391-022-00578-7

Ejemplares similares